{"id":"ibandronate-alfacalcidol-calcium","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Gastrointestinal upset (nausea, dyspepsia)"},{"rate":"5-10","effect":"Musculoskeletal pain"},{"rate":"1-5","effect":"Hypercalcemia (with excessive supplementation)"},{"rate":"<1","effect":"Osteonecrosis of the jaw (rare)"},{"rate":"<1","effect":"Atypical fractures (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ibandronate is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Alfacalcidol (1-alpha-hydroxyvitamin D3) enhances intestinal calcium absorption and promotes osteoblast differentiation, while calcium provides the mineral substrate for bone formation. Together, these agents work synergistically to increase bone mineral density and reduce fracture risk.","oneSentence":"This combination therapy inhibits bone resorption via bisphosphonate action while simultaneously promoting bone mineralization through active vitamin D and calcium supplementation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:33:12.675Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis treatment and prevention"},{"name":"Bone loss associated with postmenopausal women or glucocorticoid use"}]},"trialDetails":[{"nctId":"NCT00668330","phase":"PHASE4","title":"Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2007-04","conditions":"Systemic Lupus Erythematosus","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bonviva","placebo Bonviva"],"phase":"marketed","status":"active","brandName":"Ibandronate+alfacalcidol+calcium","genericName":"Ibandronate+alfacalcidol+calcium","companyName":"Chinese University of Hong Kong","companyId":"chinese-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy inhibits bone resorption via bisphosphonate action while simultaneously promoting bone mineralization through active vitamin D and calcium supplementation. Used for Osteoporosis treatment and prevention, Bone loss associated with postmenopausal women or glucocorticoid use.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}